Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance-based Perspectives and Clinical Updates.
Muhammad Asif,Muhammad Waqas Usman,Shahid Ayub,Sahar Farhat,Zilli Huma,Jawad Ahmed,Mohammad Amjad Kamal,Deema Hussein,Aneela Javed,Ishaq Khan
DOI: https://doi.org/10.2174/1381612826666200224112141
IF: 3.31
2020-01-01
Current Pharmaceutical Design
Abstract:Despite gigantic advances in medical research and development, chemotherapeutic resistance remains a major challenge for CNS tumors. The failure of complete eradication of CNS tumors has been correlated with the existence of several factors including over expression of transporter proteins. To date, 49 ABC-transporter proteins (ABC-TPs) are reported in humans, and the evidence of their strong association with chemotherapeutics' influx, dissemination, and efflux in CNS tumors, is growing. Research studies in CNS tumor are implicating ABC-TPs as diagnostic, prognostic and therapeutic biomarkers that may be utilised in preclinical and clinical studies. With the current advancements in cell biology, molecular analysis of genomic and transcriptomic interplay, and protein homology-based drug-transporters' interaction, our research approaches are streamlining the ABC-TPs' roles in cancers and multidrug resistance. Potential ABC-TPs' inhibitors for better clinical outcomes in CNS tumors have emerged. These include members of EZH2 inhibitors, which exhibit disparate level of selectivity for being a substrate for ABCB1 and ABCG2. Elacridar was shown to enhance chemo-sensitivity of Dasatanib and Imatinib in various glioma models. Tariquidar has improved Temozolomide's effectiveness in CNS tumors. Although these inhibitors were shown to be effective in preclinical settings, their significant clinical outcomes have not been promising in clinical trials. Molecular evaluations of ABC-TPs and their drug-interactions are being pursued in various research labs, including ours, in an effort to better comprehend their biological mechanisms that are utilised for drug resistance, and to develop novel strategies to upsurge the clinical effectiveness of anticancer chemotherapeutics, which will ultimately improve the clinical outcomes.